| Seq #117 | Friday, 10 March 2006 | |||||||||||||||||||||||
| 10:45 AM-12:15 PM Dolphin Hotel Asia 3, Symposium - Group/Division Sponsored | ||||||||||||||||||||||||
| [AADR] Medical/Dental Insurance Databases and Drug Safety Surveillance | ||||||||||||||||||||||||
Sponsored by: Behavioral Sciences | ||||||||||||||||||||||||
| Description: Recent failures of the Drug Safety Surveillance system in the United States and abroad, as evidenced by market withdrawals of commonly used medications, reminded us of the many limitations in the way we monitor long term drug safety. Although drug safety evaluation is primarily performed during clinical development, clinical trials are not efficient in identifying rare adverse effects. Similarly, the post-market system suffers from inherent limitations, including the under reporting of voluntary reports of adverse effects. As a source of healthcare utilization data, administrative insurance databases present a viable and efficient alternative for proactive safety surveillance. Several serious adverse effects have now been identified from analyzing medical claims and successful surveillance programs have been put in place in the medical field | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
Back to the: Symposium Program
Back to the ADEA/AADR/CADR Meeting & Exhibition (March 8-11, 2006)